FAQ: Wastewater Monitoring for Rapid COVID-19 Community Spread Detection
Webinar Overview
Wastewater monitoring has emerged as the fastest and most effective method for early detection of COVID-19 community spread. Join GT Molecular Director of Research and Development Dr. Rose Nash for a jargon-free discussion on the technologies in use for COVID-19 quantification in wastewater and an in-depth review of the analytical validation procedures used to validate the performance of these workflows.
Dr. Nash will answer all your questions related to wastewater monitoring at the facility and community level. She’ll lay out proven methods for developing an effective testing plan, review techniques used to produce reliable data, and discuss how monitoring data can be used to help control the spread of the virus.
Discover what we’ve learned through our work to establish the Colorado COVID-19 Surveillance Program and leave with information you can put into action.
- How wastewater monitoring for COVID-19 works
- Answers to your questions:
- How does one design a testing plan?
- What does the sampling protocol look like?
- What methods are used to quantify the virus?
- How reliable is the data?
- What does the data mean, and what can I do with it?
- How much warning of an outbreak does the data provide?
- How do I ensure that it’s actionable?
- Lessons learned from the Colorado COVID-19 Surveillance Program
- Testing-plan workflow review
- Techniques used to ensure data is reliable
- Recommendations for sampling equipment, including lease options
- Directors of Plant Operations
- University Chief Medical Officers
- Public Health Professionals
- Wastewater Facility Operators
- Environmental Specialists
- Analytical Services Officers
- Coordinators of Wastewater Treatment
- Deputy Directors
- Directors of Strategy and Innovation
- Laboratory Support Supervisors
- District Engineers
- Process Engineers
- Directors of Environmental Programs
- Clean Water Program Managers
Presenter: Dr. Rose Nash and Adam Hobson
Dr. Rose Nash is the Director of Research and Development at GT Molecular where she leads development efforts for an ultrasensitive COVID-19 diagnostic that is currently pending FDA approval. Previously, Rose served as the R&D Manager at InDevR, a Boulder biotechnology company developing new molecular tools to serve the influenza vaccine industry. Her training includes a Bachelor’s degree in Microbiology from Indiana University, a Doctorate in Microbiology from the University of Wisconsin-Madison, and two post-doctoral fellowships at the University of Colorado-Boulder.
Adam Hobson, In-Situ's lead application engineer, has recently worked with several counties and universities to establish effective sampling plans for COVID-19 detection. He has addressed data-collection challenges around the world for more than 20 years and holds a master’s degree in Civil Engineering from the University of Colorado.